Replies to post #438052 on Anavex Life Sciences Corp (AVXL)

[xodcode]

Yes, it was difficult to ignore the extremely oversold AVXL price at $5! Heck cash on hand of $140 million translates into $2 a share and the AVXL portfolio is most certainly worth multiples of $3.

Any positive RETT news will surely validate A2-73, not only for RETT, but also, AD and PD and several other diseases. And that's not factoring in A3-71 potential.

Hard to imagine the upside price impact of positive RETT news and AD journal reporting. My guess is that it will be multiples of the $3 that was priced in for the AVXL product portfolio at $5 a week ago.